TS
JANX icon

Thomas Steyer’s Janux Therapeutics JANX Stock Holding History

Thomas Steyer’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-48,000
Closed -$1.11M – 154
2025
Q2 		$1.11M Hold
48,000
– – ﹤0.01% 89
2025
Q1 		$1.3M Hold
48,000
– – 0.01% 91
2024
Q4 		$2.57M Buy
+48,000
New +$2.54M 0.01% 93

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Thomas Steyer's JANX Position: Q3 2025 in Review

Thomas Steyer sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 48,000 shares — an estimated $1.11M sold.

Thomas Steyer first reported a position in JANX in Q4 2024 and held it in 3 quarters. The position peaked at $2.57M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Thomas Steyer reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Thomas Steyer sold 48,000 Janux Therapeutics shares in Q3 2025, an estimated $1.11M.
  • Thomas Steyer first reported a position in Janux Therapeutics in Q4 2024 and held it in 3 quarters.
  • Thomas Steyer's Janux Therapeutics position peaked at $2.57M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.